Teacher Retirement System of Texas Has $233,000 Holdings in Theravance Biopharma Inc (TBPH)

Teacher Retirement System of Texas lowered its stake in Theravance Biopharma Inc (NASDAQ:TBPH) by 35.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,599 shares of the biopharmaceutical company’s stock after selling 5,332 shares during the quarter. Teacher Retirement System of Texas’ holdings in Theravance Biopharma were worth $233,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Swiss National Bank boosted its stake in Theravance Biopharma by 5.3% in the 1st quarter. Swiss National Bank now owns 75,142 shares of the biopharmaceutical company’s stock worth $1,822,000 after purchasing an additional 3,800 shares during the period. SG Americas Securities LLC bought a new stake in shares of Theravance Biopharma during the 1st quarter valued at about $130,000. Schwab Charles Investment Management Inc. boosted its position in shares of Theravance Biopharma by 4.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock valued at $5,569,000 after acquiring an additional 8,119 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of Theravance Biopharma during the 4th quarter valued at about $313,000. Finally, Alps Advisors Inc. boosted its position in shares of Theravance Biopharma by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 72,564 shares of the biopharmaceutical company’s stock valued at $1,760,000 after acquiring an additional 12,613 shares during the last quarter. Institutional investors and hedge funds own 85.62% of the company’s stock.

A number of brokerages have recently issued reports on TBPH. BidaskClub downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. ValuEngine upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, May 31st. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the company a “buy” rating in a research report on Thursday, May 24th. Needham & Company LLC reiterated a “buy” rating and set a $40.00 price target on shares of Theravance Biopharma in a research report on Wednesday, May 9th. Finally, Leerink Swann set a $31.00 price target on Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, May 9th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $39.29.



In related news, EVP Bradford J. Shafer sold 10,140 shares of the business’s stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $24.09, for a total value of $244,272.60. Following the completion of the sale, the executive vice president now owns 133,324 shares in the company, valued at approximately $3,211,775.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Bradford J. Shafer sold 14,040 shares of the business’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $23.97, for a total value of $336,538.80. Following the completion of the sale, the executive vice president now owns 133,324 shares of the company’s stock, valued at approximately $3,195,776.28. The disclosure for this sale can be found here. Insiders sold a total of 34,180 shares of company stock valued at $823,711 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Shares of TBPH opened at $23.93 on Monday. The stock has a market cap of $1.32 billion, a PE ratio of -4.39 and a beta of 1.80. Theravance Biopharma Inc has a 12-month low of $21.27 and a 12-month high of $43.44. The company has a quick ratio of 4.08, a current ratio of 4.25 and a debt-to-equity ratio of 3.53.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.04. The company had revenue of $8.32 million during the quarter, compared to the consensus estimate of $5.74 million. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. equities analysts forecast that Theravance Biopharma Inc will post -4.8 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply